50BA:F Bicycle Therapeutics plc

EUR 13.40 -5.90 ( -30.57)%
Icon

Bicycle Therapeutics plc (50BA:F) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 13.40

-5.90 (-30.57)%

EUR 1.27B

135.00

N/A

N/A

Icon

50BA:F

Bicycle Therapeutics plc (EUR)
COMMON STOCK | F
EUR 13.40
-5.90 ( -30.57)%
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 1.27B

N/A

EUR 13.40

Bicycle Therapeutics plc (50BA:F) Stock Forecast

N/A

Based on the Bicycle Therapeutics plc stock forecast from 0 analysts, the average analyst target price for Bicycle Therapeutics plc is not available over the next 12 months. Bicycle Therapeutics plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bicycle Therapeutics plc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Bicycle Therapeutics plc’s stock price was EUR 13.40. Bicycle Therapeutics plc’s stock price has changed by -25.14% over the past week, -36.79% over the past month and -8.22% over the last year.

No recent analyst target price found for Bicycle Therapeutics plc
No recent average analyst rating found for Bicycle Therapeutics plc

Company Overview Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) whic...Read More

Portway Building, Cambridge, United Kingdom, CB21 6GS

284

December

EUR

Germany

Adjusted Closing Price for Bicycle Therapeutics plc (50BA:F)

Loading...

Unadjusted Closing Price for Bicycle Therapeutics plc (50BA:F)

Loading...

Share Trading Volume for Bicycle Therapeutics plc Shares

Loading...

Compare Performance of Bicycle Therapeutics plc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for 50BA:F

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Bicycle Therapeutics plc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CSJA:F
CSL LTD SPON.ADR 2 +0.50 (+0.60%) EUR84.96B 33.27 20.82

Frequently Asked Questions About Bicycle Therapeutics plc (50BA:F) Stock

Stock Target Advisor's fundamental analysis for Bicycle Therapeutics plc's stock is Bearish.

Unfortunately we do not have enough data on 50BA:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 50BA:F's stock to indicate what its average analyst target is.

50BA:F stock's Price/Earning ratio is 1,790.56. Our analysis grades 50BA:F stock's Price / Earning ratio at F. This means that 50BA:F stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the F exchange. Based on this 50BA:F may be a overvalued for its sector.

The last closing price of 50BA:F's stock was EUR 13.40.

The most recent market capitalization for 50BA:F is EUR 1.27B.

Unfortunately we do not have enough analyst data on 50BA:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Bicycle Therapeutics plc's stock.

As per our most recent records Bicycle Therapeutics plc has 284 Employees.

Bicycle Therapeutics plc's registered address is Portway Building, Cambridge, United Kingdom, CB21 6GS. You can get more information about it from Bicycle Therapeutics plc's website at https://www.bicycletherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Frequently Asked Questions About Bicycle Therapeutics plc (50BA:F) Stock

Stock Target Advisor's fundamental analysis for Bicycle Therapeutics plc's stock is Bearish.

Unfortunately we do not have enough data on 50BA:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 50BA:F's stock to indicate what its average analyst target is.

50BA:F stock's Price/Earning ratio is 1,790.56. Our analysis grades 50BA:F stock's Price / Earning ratio at F. This means that 50BA:F stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the F exchange. Based on this 50BA:F may be a overvalued for its sector.

The last closing price of 50BA:F's stock was EUR 13.40.

The most recent market capitalization for 50BA:F is EUR 1.27B.

Unfortunately we do not have enough analyst data on 50BA:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Bicycle Therapeutics plc's stock.

As per our most recent records Bicycle Therapeutics plc has 284 Employees.

Bicycle Therapeutics plc's registered address is Portway Building, Cambridge, United Kingdom, CB21 6GS. You can get more information about it from Bicycle Therapeutics plc's website at https://www.bicycletherapeutics.com.
Loading...